

## **Materials Design Analysis Reporting (MDAR) Checklist for Authors**

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

**Materials**

<b>Antibodies</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		No Antibodies were used in this study
<b>Cell materials</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
<b>Cell lines:</b> Provide species information, strain. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number,		No cells were used in this study
<b>Primary cultures:</b> Provide species, strain, sex of origin, genetic modification status.		No Cultures were used in this study
<b>Experimental animals</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
<b>Laboratory animals:</b> Provide species, strain, sex, age, genetic modification status. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID		No Animals were used in this study
<b>Animal observed in or captured from the field:</b> Provide species, sex and age where possible		None used for this study
<b>Model organisms:</b> Provide Accession number in repository (where relevant) <b>OR</b> RRID		None used for this study
<b>Plants and microbes</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		No plants were used for this study
<b>Microbes:</b> provide species and strain, unique accession number if available, and source		No Microbes were used for this study
<b>Human research participants</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	University of Missouri IRB was obtained # 2006537 (Methods/paragraph 1)	
Provide statement confirming informed consent obtained from study participants.		Retrospective chart review, consent was waived by IRB
Report on age and sex for all study participants.	All age groups and all genders were included (Methods/paragraph 1)	

**Design**

<b>Study protocol</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.		This was a retrospective chart review focusing more on the financial impact of the treatment.
<b>Laboratory protocol</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
Provide DOI or other citation details if detailed step-by-step protocols are available.		No Laboratory work was needed for the study
<b>Experimental study design (statistics details)</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
State whether and how the following have been done, <b>or</b> if they were not carried out.		
Sample size determination		We studied all available data, no sample size was calculated
Randomisation		None done
Blinding		None Done
Inclusion/exclusion criteria	We included subjects from all ages and genders who received at least one dose of IV NAC for the treatment of APAP toxicity. We excluded subjects who received IV NAC for liver failure not associated with APAP overdose. Additionally, we excluded pregnant women and prisoners. (Methods, paragraph 1, page-7, line 5)	
<b>Sample definition and in-laboratory replication</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
State number of times the experiment was replicated in laboratory		No Lab experiments were conducted
Define whether data describe technical or biological replicates		None were used
<b>Ethics</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	University of Missouri IRB was obtained # 2006537 (Methods/paragraph 1, page 7, line 2)	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		No animals were used
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		None were used
<b>Dual Use Research of Concern (DURC)</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		None used

**Analysis**

<b>Attrition</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	All inclusion and exclusion criteria were predetermined. (Methods/ paragraph 1, page 7, line 5)	
<b>Statistics</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
Describe statistical tests used and justify choice of tests.		This was a simple descriptive data, no statistical analysis was required to show results
<b>Data Availability</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
State whether newly created datasets are available, including protocols for access or restriction on access.	All data is available with the PI, access to data is limited to one encrypted file.	
If data are publicly available, provide accession number in repository or DOI or URL.		Not publicly available
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		Not publicly available
<b>Code Availability</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		No new code or software was generated
If code is publicly available, provide accession number in repository, or DOI or URL.		No code was generated

**Reporting**

<b>Adherence to community standards</b>	<b>Yes (indicate where provided: section/paragraph)</b>	<b>n/a</b>
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication (No other checklist is provided with the manuscript.	

Article information: <http://dx.doi.org/10.21037/jhmhp-20-87>